» Articles » PMID: 8228807

Mechanisms of Class I Restricted Immunopathology. A Transgenic Mouse Model of Fulminant Hepatitis

Overview
Journal J Exp Med
Date 1993 Nov 1
PMID 8228807
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

The molecular and cellular mechanisms responsible for cytotoxic T lymphocyte (CTL)-induced immunopathology are not well defined. Using a model in which hepatitis B surface antigen (HBsAg)-specific CTL cause an acute necroinflammatory liver disease in HBsAg transgenic mice, we demonstrate that class I-restricted disease pathogenesis is an orderly, multistep process that involves direct as well as indirect consequences of CTL activation. It begins (step 1) almost immediately as a direct antigen-specific CTL-target cell interaction that triggers the HBsAg-positive hepatocyte to undergo programmed cell death (apoptosis). It progresses (step 2) within hours to a focal inflammatory response in which antigen-nonspecific lymphocytes and neutrophils amplify the local cytopathic effect of the CTL. The most destructive pathogenetic function of the CTL, however, is to secrete interferon gamma when they encounter antigen in vivo, thereby activating the intrahepatic macrophage and inducing a delayed-type hypersensitivity response (step 3) that destroys the liver and kills the mouse. We propose that the principles illustrated in this study are generally applicable to other models of class I-restricted, CTL-induced immunopathology, and we suggest that they contribute to the immunopathogenesis of viral hepatitis during hepatitis B virus infection in humans.

Citing Articles

Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies.

Lazarevic I, Banko A, Miljanovic D, Cupic M Pathogens. 2024; 13(1).

PMID: 38251353 PMC: 10818932. DOI: 10.3390/pathogens13010046.


Mouse Models for Hepatitis B Virus Infection and Their Application.

Du Y, Broering R, Li X, Zhang X, Liu J, Yang D Front Immunol. 2021; 12:766534.

PMID: 34777385 PMC: 8586444. DOI: 10.3389/fimmu.2021.766534.


T cells protect against hepatitis A virus infection and limit infection-induced liver injury.

Misumi I, Mitchell J, Lund M, Cullen J, Lemon S, Whitmire J J Hepatol. 2021; 75(6):1323-1334.

PMID: 34331968 PMC: 8604763. DOI: 10.1016/j.jhep.2021.07.019.


Interferon signaling suppresses the unfolded protein response and induces cell death in hepatocytes accumulating hepatitis B surface antigen.

Baudi I, Isogawa M, Moalli F, Onishi M, Kawashima K, Ishida Y PLoS Pathog. 2021; 17(5):e1009228.

PMID: 33979382 PMC: 8143404. DOI: 10.1371/journal.ppat.1009228.


Abnormal Innate Immunity in Acute-on-Chronic Liver Failure: Immunotargets for Therapeutics.

Khanam A, Kottilil S Front Immunol. 2020; 11:2013.

PMID: 33117329 PMC: 7578249. DOI: 10.3389/fimmu.2020.02013.


References
1.
Shu S, Fonseca L, Kato H, Zbar B . Mechanisms of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity. Cancer Res. 1983; 43(6):2637-43. View

2.
Harty J, Schreiber R, Bevan M . CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. Proc Natl Acad Sci U S A. 1992; 89(23):11612-6. PMC: 50603. DOI: 10.1073/pnas.89.23.11612. View

3.
Schultz R, KLEINSCHMIDT W . Functional identity between murine gamma interferon and macrophage activating factor. Nature. 1983; 305(5931):239-40. DOI: 10.1038/305239a0. View

4.
Yamasaki T, Handa H, Yamashita J, Watanabe Y, Namba Y, Hanaoka M . Specific adoptive immunotherapy with tumor-specific cytotoxic T-lymphocyte clone for murine malignant gliomas. Cancer Res. 1984; 44(5):1776-83. View

5.
Lehmann-Grube F, Assmann U, Loliger C, Moskophidis D, Lohler J . Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol. 1985; 134(1):608-15. View